Shanghai - Delayed Quote CNY

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)

Compare
16.45
+0.31
+(1.92%)
At close: December 27 at 3:00:02 PM GMT+8
Loading Chart for 603858.SS
DELL
  • Previous Close 16.14
  • Open 16.17
  • Bid 16.44 x --
  • Ask 16.45 x --
  • Day's Range 16.10 - 16.54
  • 52 Week Range 14.15 - 19.70
  • Volume 5,034,509
  • Avg. Volume 6,975,252
  • Market Cap (intraday) 18.194B
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) --
  • EPS (TTM) -0.26
  • Earnings Date --
  • Forward Dividend & Yield 0.13 (0.77%)
  • Ex-Dividend Date Aug 20, 2024
  • 1y Target Est --

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. The company offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. Shandong Buchang Pharmaceuticals Co., Ltd. was founded in 1993 and is based in Heze, China.

www.buchang.com

8,311

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603858.SS

View More

Performance Overview: 603858.SS

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

603858.SS
2.50%
SSE Composite Index
14.29%

1-Year Return

603858.SS
0.57%
SSE Composite Index
17.29%

3-Year Return

603858.SS
11.48%
SSE Composite Index
6.02%

5-Year Return

603858.SS
5.71%
SSE Composite Index
13.06%

Compare To: 603858.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603858.SS

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    18.19B

  • Enterprise Value

    20.71B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.53

  • Price/Book (mrq)

    1.63

  • Enterprise Value/Revenue

    1.76

  • Enterprise Value/EBITDA

    28.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.49%

  • Return on Assets (ttm)

    1.75%

  • Return on Equity (ttm)

    -4.04%

  • Revenue (ttm)

    11.78B

  • Net Income Avi to Common (ttm)

    -293.31M

  • Diluted EPS (ttm)

    -0.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.31B

  • Total Debt/Equity (mrq)

    36.39%

  • Levered Free Cash Flow (ttm)

    1.19B

Research Analysis: 603858.SS

View More

People Also Watch